Literature DB >> 15772145

Patient adherence to prescribed antimicrobial drug dosing regimens.

Bernard Vrijens1, John Urquhart.   

Abstract

The aim of this article is to review current knowledge about the clinical impact of patients' variable adherence to prescribed anti-infective drug dosing regimens, with the aim of renewing interest and exploration of this important but largely neglected area of therapeutics. Central to the estimation of a patient's adherence to a prescribed drug regimen is a reliably compiled drug dosing history. Electronic monitoring methods have emerged as the virtual 'gold standard' for compiling drug dosing histories in ambulatory patients. Reliably compiled drug dosing histories are consistently downwardly skewed, with varying degrees of under-dosing. In particular, the consideration of time intervals between protease inhibitor doses has revealed that ambulatory patients' variable execution of prescribed dosing regimens is a leading source of variance in viral response. Such analyses reveal the need for a new discipline, called pharmionics, which is the study of how ambulatory patients use prescription drugs. Properly analysed, reliable data on the time-course of patients' actual intake of prescription drugs can eliminate a major source of unallocated variance in drug responses, including the non-response that occurs and is easily misinterpreted when a patient's complete non-execution of a prescribed drug regimen is unrecognized clinically. As such, reliable compilation of ambulatory patients' drug dosing histories has the promise of being a key step in reducing unallocated variance in drug response and in improving the informational yield of clinical trials. It is also the basis for sound, measurement-guided steps taken to improve a patient's execution of a prescribed dosing regimen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772145     DOI: 10.1093/jac/dki066

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  33 in total

Review 1.  "Why do they do that?" The compliance conundrum.

Authors:  Thomas E Nevins
Journal:  Pediatr Nephrol       Date:  2005-05-24       Impact factor: 3.714

2.  A pharmacokinetic formalism explicitly integrating the patient drug compliance.

Authors:  Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

3.  Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics.

Authors:  Laetitia Comté; Bernard Vrijens; Eric Tousset; Paul Gérard; John Urquhart
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-12       Impact factor: 2.745

4.  A probabilistic approach for the evaluation of pharmacological effect induced by patient irregular drug intake.

Authors:  Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

Review 5.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

Review 6.  Methodological lessons from clinical trials and the future of microbicide research.

Authors:  Ariane van der Straten; Elizabeth T Montgomery; Miriam Hartmann; Alexandra Minnis
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

7.  Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.

Authors:  Jean-Jacques Parienti; Aurélie Barrail-Tran; Xavier Duval; Georges Nembot; Diane Descamps; Marie Vigan; Bernard Vrijens; Xavière Panhard; Anne-Marie Taburet; France Mentré; Cécile Goujard
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 8.  A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence.

Authors:  Mohamed El Alili; Bernard Vrijens; Jenny Demonceau; Silvia M Evers; Mickael Hiligsmann
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

9.  [Compliance enhancement in drug therapy : opportunities and limitations].

Authors:  L Krolop; U Jaehde
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

10.  Topical retapamulin in the management of infected traumatic skin lesions.

Authors:  Ribhi Shawar; Nicole Scangarella-Oman; Marybeth Dalessandro; John Breton; Monique Twynholm; Gang Li; Harmony Garges
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.